Chemistry Reference
In-Depth Information
48. Konno, H., Handa, T., Alonzo, D.E., and Taylor, L.S. (2008) Effect of polymer type on the
dissolution profile of amorphous solid dispersions containing felodipine.
Eur. J. Pharm.
Biopharm.
, 70(2):493-499.
49. Kwong, A.D., Kauffman, R.S., Hurter, P., and Mueller, P. (2011) Discovery and develop-
ment of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C
virus.
Nat. Biotechnol.
, 29(11):993-1003.
50. Law, D., Krill, S.L., Schmitt, E.A., et al. (2001) Physicochemical considerations in the
preparation of amorphous ritonavir
-
poly(ethylene glycol) 8000 solid dispersions.
J. Pharm.
Sci.
, 90(8):1015-1025.
51. Law, D., Schmitt, E.A., Marsh, K.C., et al. (2004) Ritonavir-PEG 8000 amorphous solid
dispersions:
in vitro
and
in vivo
evaluations.
J. Pharm. Sci.
, 93(3):563-570.
52. Leuner, C. and Dressman, J. (2000) Improving drug solubility for oral delivery using solid
dispersions.
Eur. J. Pharm. Biopharm.
, 50(1):47-60.
53. Six, K., Verreck, G., Peeters, J., Brewster, M., and Van Den Mooter, G. (2004) Increased
physical stability and improved dissolution properties of itraconazole, a class II drug, by solid
dispersions that combine fast- and slow-dissolving polymers.
J. Pharm. Sci.
, 93(1):124-131.
54. Ilevbare, G.A. and Taylor, L.S. (2013) Liquid-liquid phase separation in highly super-
saturated aqueous solutions of poorly water-soluble drugs: implications for solubility
enhancing formulations.
Cryst. Growth Des.
, 13(4):1497-1509.
55. Murdande, S., Pikal, M., Shanker, R., and Bogner, R. (2010) Solubility advantage of
amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for
prediction of solubility enhancement
in structurally diverse insoluble pharmaceuticals.
Pharm. Res.
, 27(12):2704-2714.
56. Murdande, S.B., Pikal, M.J., Shanker, R.M., and Bogner, R.H. (2010) Solubility advantage
of amorphous pharmaceuticals: I. A thermodynamic analysis.
J. Pharm. Sci.
, 99(3):
1254-1264.
57. Hoffman, J.D. (1958) Thermodynamic driving force in nucleation and growth processes.
J. Chem. Phys.
, 29(5):1192-1193.
58. Mullin, J.W. (2001)
Solutions and Solubility
, 4th ed., Butterworth-Heinemann, Oxford,
pp. 86-134.
59. Ilevbare, G.A., Liu, H., Edgar, K.J., and Taylor, L.S. (2012) Maintaining supersaturation in
aqueous drug solutions: impact of different polymers on induction times.
Cryst. Growth Des.
,
13(2):740-751.
60. Guzmán, H.R., Tawa, M., Zhang, Z., et al. (2007) Combined use of crystalline salt forms and
precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations.
J. Pharm. Sci.
, 96(10):2686-2702.
61. Calahan, J.L., Zanon, R.L., Alvarez-Nunez, F., and Munson, E.J. (2013) Isothermal
microcalorimetry to investigate the phase separation for amorphous solid dispersions of
AMG 517 with HPMC-AS.
Mol. Pharm.
, 10(5):1949-1957.
62. Engers, D., Teng, J., Jimenez-Novoa, J., et al. (2008) Screening and animal bioavailability
studies on itraconazole amorphous dispersions.
AAPS Annual Meeting, Atlanta, Georgia
.
63. Bak, A., Gore, A., Yanez, E., et al. (2008) The co-crystal approach to improve the exposure of
a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharma-
cokinetics.
J. Pharm. Sci.
, 97(9):3942-3956.
64. Alonzo, D.E., Gao, Y., Zhou, D., Mo, H., Zhang, G.G., and Taylor, L.S. (2011) Dissolution and
precipitation behavior of amorphous solid dispersions.
J. Pharm. Sci.
, 100(8):3316-3331.
